Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2017

Kim, D. K.; Riley, Laura E.; Harriman, Kathleen; Hunter, Paul; Bridges, Carolyn B.

doi:10.1111/ajt.14244

Cited by 11 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recommendations for vaccination are outlined in the Centers for Disease Control and Prevention and Advisory Committee on Immunization Practices guidelines . Follow‐up testing is recommended for those who remain at risk of infection, such as HCWs, infants of HBsAg‐positive mothers, sexual partners of persons with CHB, chronic hemodialysis patients, and immunocompromised persons, including those with HIV.…”

Section: Screening Counseling and Prevention Of Hepatitis Bmentioning

confidence: 99%

Update on prevention, diagnosis, and treatment of chronic hepatitis B

et al. 2018

View full text Add to dashboard Cite

Section: Screening Counseling and Prevention Of Hepatitis Bmentioning

confidence: 99%

Update on prevention, diagnosis, and treatment of chronic hepatitis B

et al. 2018

View full text Add to dashboard Cite

“…As a patient with certain non‐malignant immune‐mediated hematologic disorder may eventually undergo splenectomy and given the impaired response to vaccination demonstrated in patients after treatment with rituximab, it may be worthwhile to vaccinate the patient, who is to be treated with rituximab, against encapsulated microorganisms. As an example, in ITP patients, the American Society of Hematology (ASH) and the CDC recommend: (a) immunization against S. pneumoniae , H. influenzae , and N. meningitidis , administered at least 2 weeks before immunosuppressive therapy in anticipation that some patients will eventually go on to require splenectomy; and (b) patients should be counseled on the potential risk of vaccine unresponsiveness after rituximab . European guidelines recommend vaccination of all patients receiving rituximab …”

Section: Rituximabmentioning

confidence: 99%

“…It also highlights areas where limited evidence exists and discusses our clinical approach given the existent knowledge base. Finally, the available data and suggested management strategies for the prevention of infection in patients treated with these agents are summarized in Table …”

Section: Introductionmentioning

confidence: 99%

Preventing infectious complications when treating non‐malignant immune‐mediated hematologic disorders

2019

View full text Add to dashboard Cite

Immunosuppressants, targeted antibody therapies, and surgical splenectomy are amongst the treatment choices for immune-mediated non-malignant hematologic disorders, with infection being the most common non-hematological adverse event from these therapies. Corticosteroids are associated with a length-of-treatment and dose-dependent risk for infection, including opportunistic infections. Screening and antimicrobial prophylaxis against tuberculosis, Strongyloides stercoralis, and Pneumocystis jirovecii pneumonia, are indicated in selected patients on steroids and with certain risk factors for infection. Rituximab is associated with hepatitis B virus reactivation. All patients planned to be started on rituximab should be screened for hepatitis B surface antigen and total core antibody, with antiviral prophylaxis given depending on test results. In eculizumab treated patients, immunization against meningococcal serogroups ACWY and B is recommended. In addition, some guidelines suggest antibiotic prophylaxis for the duration of eculizumab treatment. In splenectomized patients, counseling and immunization are cornerstones of infection prevention. Several federal and society guidelines about immunizations and prophylactic antimicrobial therapies for patients treated with various immunosuppressive agents exist and are summarized in this manuscript in a clinical-focused table. In addition, management suggestions are made where no formal guidelines exist. 2 | PATIENT COUNSELING An important part of infectious disease prevention in immunocompromised patients entails the education of the patient, family, and friends. Household and other close contacts of persons with altered immunocompetence should be educated in hand hygiene and avoid contact with the patient when they are experiencing an infectious process. 12 Proper food and water hygiene measures are important to prevent

show abstract

“…Live vaccination may interfere with the reading of Tuberculin skin test (TST) which is commonly done in most transplant cenetrs for all potential recipients. Therefore, the TST should be performed simultaneously with live vaccination or delayed by at least 28 d[ 11 ]. Similar difficulties with interpretation have also been reported with the newer interferon gamma release assay (IGRA)[ 12 ].…”

Section: Timing Of Vaccinationmentioning

confidence: 99%

“…Therefore, vaccination is recommended for all prospective elderly recipients (≥ 60 years) at least 1 mo before RT. In those aged 50-60 years, vaccination is optional and can be considered in those who have a history of varicella or zoster infection[ 11 ]. There is no clear evidence for its benefit in recipients younger than 50 years.…”

Section: Common Vaccines In the Transplant Patientmentioning

confidence: 99%

Vaccination practices in End Stage Renal Failure and Renal Transplantation; Review of current guidelines and recommendations

Gunawansa

Rathore

Sharma

et al. 2018

WJT

View full text Add to dashboard Cite

Due to the increased burden of infectious complications following solid organ transplantation, vaccination against common pathogens is a hugely important area of discussion and application in clinical practice. Reduction in infectious complications will help to reduce morbidity and mortality post-transplantation. Immunisation history is invaluable in the work-up of potential recipients. Knowledge of the available vaccines and their use in transplant recipients, donors and healthcare providers is vital in the delivery of quality care to transplant recipients. This article will serve as an aide-memoire to transplant physicians and health care professionals involved in managing transplant recipients as it provides an overview of different types of vaccines, timing of vaccination, vaccines contraindicated post solid organ transplantation and travel vaccines.

show abstract

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2017

Cited by 11 publications

References 5 publications

Update on prevention, diagnosis, and treatment of chronic hepatitis B

Update on prevention, diagnosis, and treatment of chronic hepatitis B

Preventing infectious complications when treating non‐malignant immune‐mediated hematologic disorders

Vaccination practices in End Stage Renal Failure and Renal Transplantation; Review of current guidelines and recommendations

Contact Info

Product

Resources

About